Results 51 to 60 of about 34,778 (264)

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives

Cost Effectiveness and Resource Allocation, 2021
Background A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes ...
Zoltán Kaló, Zsuzsanna Ida Petykó, Frank-Ulrich Fricke, Nikos Maniadakis, Tomáš Tesař, Kateřina Podrazilová, Jaime Espin, András Inotai   +7 more
doaj   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

The experience of implementing a social health insurance programme at health facilities in Khyber-Pakhtunkhwa, Pakistan

Journal of the Pakistan Medical Association
Objective:To explore the experiences of key stakeholders, including hospital managers, clinicians, and hospital-based State Life Insurance Corporation (SLIC) representatives, SCP's implementation challenges and successes.
Shifa Salman Habib, Anum Shaikh, Kiran Sohail Azeemi, Waqas Hameed, Junaid Ur Rehman Siddiqui, Ali Hussaini, Asma Altaf Hussain Merchant, Adil Haider, Sameen Siddiqi   +8 more
doaj   +1 more source

Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans

Arthritis &Rheumatology, Accepted Article.
Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

The effects of reimbursement mechanisms on medical technology diffusion in the hospital sector in the Italian NHS [PDF]

Health Policy, 2014
The aim of this study was to investigate how the differences across the regional reimbursement mechanisms and in particular the use of the DRGs impact on the level in the high technology equipment diffusion.Based on hospital sector data at a regional level we build up indicators to measure the regional diffusion of high technological medical equipment ...
Finocchiaro Castro M, Guccio C, Pignataro G, Rizzo I.   +3 more
openaire   +4 more sources

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Telemedicine Public Reimbursement Models for National and Subnational Jurisdictions: Scoping Review

Journal of Medical Internet Research
BackgroundTelemedicine has transformed health care delivery, offering improved access, efficiency, and potentially cost-effectiveness. However, wide-scale implementation is challenged due to multiple factors.
Evan Huang-Ku, Panchanok Muenkaew, Kinanti Khansa Chavarina, Yin May Tun, Zin Nwe Win, Wanrudee Isaranuwatchai, Saudamini Vishwanath Dabak, Natasha Howard   +7 more
doaj   +1 more source